ANI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANIP)

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals Inc (NASDAQ:ANIP) announced its quarterly earnings data on Wednesday, August, 7th. The specialty pharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.18 by $0.26. The specialty pharmaceutical company had revenue of $54.36 million for the quarter, compared to analysts' expectations of $55.20 million. ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. The business's revenue was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.13 EPS. View ANI Pharmaceuticals' Earnings History.

ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for ANI Pharmaceuticals.

ANI Pharmaceuticals issued an update on its FY19 earnings guidance on Wednesday, August, 7th. The company provided earnings per share (EPS) guidance of $5.57-6.21 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.01. The company issued revenue guidance of $220-226 million, compared to the consensus revenue estimate of $239.80 million.

4 analysts have issued twelve-month price targets for ANI Pharmaceuticals' shares. Their forecasts range from $76.00 to $90.00. On average, they anticipate ANI Pharmaceuticals' stock price to reach $84.25 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals.

Headlines about ANIP stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ANI Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for ANI Pharmaceuticals.

ANI Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,490,000 shares, an increase of 19.2% from the August 30th total of 1,250,000 shares. Based on an average daily trading volume, of 154,900 shares, the days-to-cover ratio is currently 9.6 days. Approximately 16.3% of the shares of the stock are sold short. View ANI Pharmaceuticals' Current Options Chain.

Some companies that are related to ANI Pharmaceuticals include Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), United Therapeutics (UTHR), FibroGen (FGEN), Evotec (EVTCY), Allakos (ALLK), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Genmab A/S (GMAB), Emergent Biosolutions (EBS), HUTCHISON CHINA/S (HCM) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Broadcom (AVGO), Micron Technology (MU), Alibaba Group (BABA), Celgene (CELG), NVIDIA (NVDA), NXP Semiconductors (NXPI) and Skyworks Solutions (SWKS).

ANI Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Regent Investment Management LLC (0.33%), Perkins Capital Management Inc. (0.19%), Calamos Advisors LLC (0.15%), Virginia Retirement Systems ET AL (0.09%), Strs Ohio (0.08%) and State of Alaska Department of Revenue (0.06%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer, Thomas Haughey and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals.

ANIP stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Nisa Investment Advisors LLC, Virginia Retirement Systems ET AL and Nwam LLC. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, James G Marken, Meridian Venture Partners Ii L and Robert W Schrepfer. View Insider Buying and Selling for ANI Pharmaceuticals.

ANIP stock was acquired by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, State of Alaska Department of Revenue, Campbell & CO Investment Adviser LLC, Robeco Institutional Asset Management B.V., Regent Investment Management LLC and Strs Ohio. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash and Thomas Haughey. View Insider Buying and Selling for ANI Pharmaceuticals.

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANIP stock can currently be purchased for approximately $78.19.

ANI Pharmaceuticals has a market capitalization of $946.10 million and generates $201.58 million in revenue each year. The specialty pharmaceutical company earns $15.49 million in net income (profit) each year or $4.61 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.View Additional Information About ANI Pharmaceuticals.

The official website for ANI Pharmaceuticals is http://www.anipharmaceuticals.com/.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]